Pharmacy Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Pharmacy Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Eur J Hosp Pharm. 2022 Mar;29(e1):e2-e5. doi: 10.1136/ejhpharm-2021-002776. Epub 2021 Aug 16.
Nosocomial bloodstream infection (nBSI) is an important clinical concern among COVID-19 hospitalised patients. It can cause sepsis and septic shock leading to high morbidity, mortality, and the emergence of antibiotic resistance. The aim of this case-control study is to identify the risk factors associated with the nBSI development in COVID-19 hospitalised patients and its incidence.
A retrospective case-control study will be performed. Cases will include nBSI episodes of adult patients (≥18 years) admitted to Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, from April to December 2020 with a diagnosis of SARS-CoV-2 pneumonia. Patients transferred from other hospitals will be excluded. Controls will include hospitalisation episodes of COVID-19 patients without nBSI. We will recruit a minimum of 74 nBSI episodes (cases) and 74 controls (according to sample size calculation). We will collect data on sociodemographics, clinical status at admission, hospital admission, in-hospital mortality, and exposure data (use of antivirals, glucocorticoids or immunomodulatory agents, length of hospitalisation, and use of medical devices such as intravenous catheters). A bivariate and a subsequent multivariate regression analysis will be performed to assess the independent effect of the associated risk factors after adjusting for confounders. The nBSI incidence rate will be estimated according to the number of nBSI episodes in admitted COVID-19 patients among the total person-month of follow-up.
The protocol of this study was approved by the Ethical Committee for Drug Investigation of the Hospital Universitari Germans Trias i Pujol. The results of this case-control study will be published in a peer reviewed journal.
医院获得性血流感染(nBSI)是 COVID-19 住院患者的一个重要临床关注点。它可导致脓毒症和感染性休克,从而导致高发病率、死亡率和抗生素耐药性的出现。本病例对照研究的目的是确定与 COVID-19 住院患者 nBSI 发展及其发生率相关的危险因素。
将进行回顾性病例对照研究。病例将包括 2020 年 4 月至 12 月期间在西班牙巴塞罗那 Germans Trias i Pujol 大学医院因 SARS-CoV-2 肺炎住院的成年(≥18 岁)nBSI 发作的患者。将排除从其他医院转来的患者。对照将包括无 nBSI 的 COVID-19 患者的住院发作。我们将招募至少 74 例 nBSI 发作(病例)和 74 例对照(根据样本量计算)。我们将收集社会人口统计学、入院时临床状况、住院、院内死亡率和暴露数据(抗病毒药物、糖皮质激素或免疫调节药物的使用、住院时间以及静脉导管等医疗器械的使用)。将进行单变量和随后的多变量回归分析,以调整混杂因素后评估相关危险因素的独立影响。根据住院 COVID-19 患者中 nBSI 发作的数量以及随访总人月数,估计 nBSI 发生率。
本研究方案已获得 Germans Trias i Pujol 大学医院药物研究伦理委员会的批准。本病例对照研究的结果将发表在同行评议的期刊上。